FDA Warns Consumers of Hidden Drug Ingredients in Certain Xcelerated Weight Loss Products

July 26, 2016

On Friday, July 22nd , the FDA published three public notifications warning consumers of hidden drug ingredients that are present in various Xcelerated Weight Loss products.  Two of the company’s products, Xcelerated Weight Loss Charged Up and Xcelerated Weight Loss Turbo Charge, have been found to contain sibutramine, a controlled substance, removed from the market for safety reasons in October 2010.  In its notice, the FDA states that these products pose a “threat to consumers because sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.”  The Agency also notes the products could also have life-threatening interactions with other medications that consumers may be taking.

FDA’s third warning concerns Xcelerated Weight Loss Ultra Max, which has been found to contain phenolphthalein and sildenafil based on a laboratory analysis conducted by the FDA.  According to the Agency’s notice, studies involving phenolphthalein indicate that it presents a cancer-causing risk in previous studies.  Among its approved indications, Sildenafil is the active ingredient in Viagra, the FDA-approved drug indicated for the treatment of erectile dysfunction (ED).  In its public notification, FDA states that “this undeclared ingredient may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels. Men with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.”

FDA is advising consumers not to purchase or use these products, which are available online and in select retail stores.  In addition, FDA encourages patients and healthcare professionals to report any adverse events or side effects associated with the use of these products to its MedWatch Safety Information and Adverse Event Reporting Program.

Are you in the process of developing a dietary supplement? Do you have a supplement that you’re looking to verify is compliant with all FDA regulations? We can help you achieve a successful interaction with FDA.  To learn more about our services and how we can help you, contact us today.


July 27, 2022

FDA announces the availability of a proposed rule: Revising the National Drug Code Format and Drug Label Barcode Requirements

On July 22, 2022, FDA announced the availability of a proposed rule, Revising the National Drug Code Format and Drug Label Barcode Requirements (Docket No. FDA-2021-N-1351), that is intended to...

August 16, 2016

FDA Warns Consumers of Numerous Products Containing Hidden Drug Ingredients

On August 9, 2016, the FDA issued five public notifications advising consumers not to purchase or use a number of products, including: Citrus’ Fit Adelgazantes R-II Boss-Rhino Gold X-tra Strength...

March 22, 2022

FDA Issues Guidance on Certain Ophthalmic Products: Policy for Compliance with 21 CFR Part 4

The U.S. Food and Drug Administration today issued the guidance for industry, Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4. This guidance provides information to...